SEC Form 4 · accession 0001106578-26-000101
UNITED THERAPEUTICS Corp · UTHR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Martine A Rothblatt
Officer — Chairperson & CEO · Director
Period of report
Jul 17, 2026
Accepted (ET)
Jul 20, 2026 · 4:32 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001082554
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 17, 2026 | M | 9,500 | $135.42 | A | 333,943 | I | by Trust |
| Common StockF3,F2 | Jul 17, 2026 | S | 240 | $528.91 | D | 333,703 | I | by Trust |
| Common StockF4,F2 | Jul 17, 2026 | S | 240 | $530.8333 | D | 333,463 | I | by Trust |
| Common StockF5,F2 | Jul 17, 2026 | S | 720 | $534.5681 | D | 332,743 | I | by Trust |
| Common StockF6,F2 | Jul 17, 2026 | S | 2,350 | $535.5258 | D | 330,393 | I | by Trust |
| Common StockF7,F2 | Jul 17, 2026 | S | 2,110 | $536.3588 | D | 328,283 | I | by Trust |
| Common StockF8,F2 | Jul 17, 2026 | S | 1,160 | $537.4466 | D | 327,123 | I | by Trust |
| Common StockF9,F2 | Jul 17, 2026 | S | 423 | $538.7026 | D | 326,700 | I | by Trust |
| Common StockF10,F2 | Jul 17, 2026 | S | 821 | $539.6266 | D | 325,879 | I | by Trust |
| Common StockF11,F2 | Jul 17, 2026 | S | 251 | $540.6925 | D | 325,628 | I | by Trust |
| Common StockF12,F2 | Jul 17, 2026 | S | 892 | $542.0634 | D | 324,736 | I | by Trust |
| Common StockF13,F2 | Jul 17, 2026 | S | 293 | $542.4309 | D | 324,443 | I | by Trust |
| Common Stock | holding | — | — | — | 40,513 | D | ||
| Common Stock | holding | — | — | — | 166 | I | by Spouse | |
| Common StockF14 | holding | — | — | — | 249,108 | I | by Trust | |
| Common StockF15 | holding | — | — | — | 45,596 | I | by Trust | |
| Common StockF16 | holding | — | — | — | 8,902 | I | by Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF17 | $135.42 | Jul 17, 2026 | M | 9,500 | D | Mar 15, 2023 | Mar 15, 2027 | Common Stock | 9,500 | 322,410 | I |
Explanation of responses
- F1This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10This transaction was executed in multiple trades at prices ranging from $539.14 to $540.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11This transaction was executed in multiple trades at prices ranging from $540.20 to $541.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12This transaction was executed in multiple trades at prices ranging from $541.37 to $542.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13This transaction was executed in multiple trades at prices ranging from $542.38 to $542.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F15Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F16Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F17Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3This transaction was executed in multiple trades at prices ranging from $528.39 to $529.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This transaction was executed in multiple trades at prices ranging from $530.80 to $530.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5This transaction was executed in multiple trades at prices ranging from $533.97 to $534.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6This transaction was executed in multiple trades at prices ranging from $534.99 to $535.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7This transaction was executed in multiple trades at prices ranging from $536.00 to $536.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8This transaction was executed in multiple trades at prices ranging from $537.07 to $538.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9This transaction was executed in multiple trades at prices ranging from $538.12 to $539.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.